Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Uterine Cervical Neoplasms 1Solid Neoplasms 1SCLC 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Metastatic Solid Tumors 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

pembrolizumab 44Paclitaxel 37Carboplatin 30Doxorubicin 11Cisplatin 11Bevacizumab 11lenvatinib 9Nivolumab 9Docetaxel 9Fulvestrant 8Gemcitabine 7Oxaliplatin 6Fluorouracil 6Pemetrexed 5Letrozole 5Ipilimumab 5Cetuximab 5spartalizumab 4selinexor 4dostarlimab 4Trastuzumab 4Irinotecan 4trastuzumab deruxtecan 3tisotumab vedotin 3serabelisib 3sacituzumab govitecan 3ribociclib 3olaparib 3epacadostat 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Endometrial Neoplasms × Platinum × Clear all
NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
626 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡